Neuroprotective features of phytoadaptogens

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk

Volumn , Issue 4, 2008, Pages 47-50

  Bocharov, Ye V ^a   Kucheryanu, V G ^a   Bocharova, O A ^a   Karpova, R V ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 45249086588     PISSN: 08696047     EISSN: 24143545     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Russian source
2. Hauser R. A., Zesiewicz T. A. Sertaline for the treatment of depression in Parkinson's disease. J. Neural Transm. 1997; 104 (2): 451-459.
3. de Lau L. M., Breteler M. M. Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5 (6): 525-535.
4. Schrag A., Schott J. M. Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol. 2006; 5 (4): 355-363.
5. Jellinger K. A. The role of iron in neurodegeneration. Prospects for pharmacotherapy of Parkinson's disease. Drug & Aging 1999; 14 (2): 115-140.
6. Carvey P. M., Punati A., Newman M. B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006; 15 (3): 239-250.
7. Russian source
8. Russian source
9. Cadet J. L., Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. 1998; 32 (2): 117-131.
10. Schapira A. H. Etiology of Parkinson's disease. Neurology 2006; 66 (10): 10-23.
11. Russian source
12. Russian source
13. Blazejova K., Nevsimalova S., Illnerova H. et al. Sleepdisorders and the 24-hour profile of melatonin and cortisol. Sborn. Lek. 2000; 101 (4): 347-351.
14. Lloberas J., Celada A. Effect of aging on macrophage function. Exp. Gerontol. 2002; 37 (12): 1325-1331.
15. Hakansson A., Westberg L., Nibson S. et al. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am. J. Med. Genet. Neuropsychiatr. Genet. 2005; 133 (1): 88-92.
16. Russian source
17. Russian source
18. Russian source
19. Russian source
20. Stern M. B. Contemporary approaches to the pharmacotherapeutic management of Parkinson's disease: an overview. Neurology 1997; 49: 2-9.
21. Soderstrom K, O'Malley J., Steece-Collier K. et al. Neural repair strategies for Parkinson's disease: insights from primate models. Cell Transplant. 2006; 15 (3): 251-265.
22. Ogawa N., Asanuma M., Miyazaki I. et al. L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease. J. Neurol. 2005; 252 (4): 23-31.
23. Kulkantrakom K., Tiamkao S., Pongchaiyakul C., Pulkes T. Levodopa induced motor complications in Thai Parkinson's disease patients. J. Med. Assoc. Thailand 2006; 89 (5): 632-637.
24. Yao X. H., Li X. J. Protective effects and its mechanism of panaxatriol saponins isolated from Panax notoginseng on cerebral ischemia. Zhongguo Zhong Yao Za Zhi 2002; 27 (5): 371-373.
25. Bu Y., Jin Z. H., Park S. Y. et al. Siberian ginseng reduces infarct volume in transient focal cerebral ischaemia in Sprague-Dawley rats. Phytother. Res. 2005; 19 (2): 167-169.
26. Kim E. H., Jang M. H., Shin M. C. et al. Protective effect of aqueous extract of Ginseng radix against 1-methyl-4-phenylpyridinium-induced apoptosis in PC12 cells. Biol. Pharm. Bull. 2003; 26: 1668-1673.
27. Lee J. Y., Kim J. W., Cho S. D. et al. Protective effect of ginseng extract against apoptotic cell death induced by 2,2′,5,5′- tetrachlorobiphenyl in neuronal SK-N-MC cells. Life Sci. 2004; 75 (13): 1621-1634.
28. Lee J. H., Kim S., Bae C. et al. Protective effect of ginsenosides, active ingredients of Panax ginseng, on kainic asid-induced neurotoxicity in rat hippocampus. Neurosci. Lett. 2002; 325 (2): 129-133.
29. Kim J. H., Kim S., Yoon I. S. et al. Otective effects of ginseng saponins on 3-nitropropionic acid-induced striatal degeneration in rats. Neuropharmacology 2005; 48 (5): 743-756.
30. Wang F. Z., Ding A. S., Liu Z. W. Effect of ginsenosides against anoxic damage of hippocampal neurons in culture. Zhongguo Yao Li Xue Bao 1995; 16 (5): 419-422.
31. Bao H. Y., Zhang J., Yeo S. J. et al. Memory enhancing and neuroprotective effects of selected ginsenosides. Pharmacology. 1991; 42 (4): 223-229.
32. Kurimoto H., Nishijo H., Uwano T. et al. Effects of nonsaponin fraction of red ginseng on learning deficits in aged rats. Physiol. Behav. 2004; 82 (2-3): 345-355.
33. Tian J., Fu F., Geng M. et al. Neuroprotective effect of 20(S)-ginsenoside Rg3 on cerebral ischemia in rats. Neurosci. Lett. 2005; 374 (2): 92-97.
34. Zhang Y. G., Liu T. P. Influences of ginsenosides Rb1 and Rg1 on reversible focal brain ischemia in rats. Zhongguo Yao Li Xue Bao 1996; 17 (1): 44-48.
35. Park E. K., Choo M. K., Oh J. K. et al. Ginsenoside Rh2 reduces ischemic brain injury in rats. Biol. Pharm. Bull. 2004; 27 (3): 433-436.
36. Park J. K., Namgung U., Lee C. J. et al. Calcium-independent CaMKII activity is involved in ginsenoside Rb1-mediated neuronal recovery after hypoxic damage. Life Sci. 2005; 76 (9): 1013-1025.
37. Kim S., Ahn K., Oh T. H. et al. Inhibitory effect of gensenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem. Biophys. res. Commun. 2002; 296 (2): 247-254.
38. +-affected mesencephalic dopaminergic cells. J. Neural Transm. 2004; 111 (6): 37-45.
39. Kim Y. C., Kim S. R., Markelonis G. J. et al. Ginsenosides Rb1 and Rg3 protect cultured rat cortical cells from glutamate-induced neurodegeneration. J. Neurosci. Res. 1998; 54 (1): 426-432.
40. Rudakewich M., Ba F., Benishin C. G. Neurotrophic and neuroprotective actions of ginsenosides Rb(1) and Rg(1). Planta Med. 2001; 67 (6): 533-537.
41. Watanabe H., Ogura T., Hosoya M. et al. Diuretic effect of cilazapril and dopamine system in the spontaneously hypertensive rat. Acta Med. Okayama 1995; 49 (5): 247-252.
42. Tanner C. M., Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv. Neurol. 1999; 80 (3): 153-159.
43. Russian source
44. Russian source
45. Russian source
46. Russian source
47. Russian source
48. Russian source
49. Kim S. H., Cho C. K., Yoo S. Y. et al. In vivo radiprotective activity of Panax Ginseng and diethildithiocarbamate. Vivo 1993; 7 (5): 467-470.
50. Russian source
51. Devaleou P., Lallouette P., Tessier A. Stimulation of the phagocitic activity of reticulo-endothelial sistem by plant drugs. Planta Med. 1980; 40 (7): 49-54.
52. Levenson D. Physicians should increase knowledge of herbal remedies. Rep. Med. Guidel Outcomes Res. 2001; 12 (15): 7-9.
53. Shin J. Y., Song J. Y., Yun Y. S. et al. Immunostimulating effects of acidic polysaccharides extract of Panax ginseng on macrophage function. Immunopharmacol. Immunotoxicol. 2002; 24 (3): 469-482.
54. Yoon T. J., Yoo Y. C., Lee S. W. et al. Anti-metastatic activiti of Acanthopanax senticosus extract and its possible immunological mechanism of action. J. Ethnopharmacol. 2004; 93 (2-3): 247-253.
55. Lee E. J., Ko E., Lee J. et al. Ginsenoside Rg1 enhances CD4+ T-cell activities and modulates Th1/Th2 differentiation. Int. Immunopharmacol. 2004; 4 (2): 235-244.
56. Yu J. L., Dou D. Q., Chen X. H. et al. Protopanaxatriol-type ginsenosides differentially modulate type 1 and type 2 cytokines production from murine splenocytes. Planta Med. 2005; 71 (3): 202-207.
57. Rai D., Bhatia G., Sen T. et al. Anti-stress effects of Ginkgo biloba and Panax ginseng: a comparative study. J. Pharmacol. Sci. 2003; 93 (4): 458-464.
58. Kaneko H., Nakanishi K. Proof of the mysterious efficacy of ginseng: basic and clinical effects of medical ginseng? Korean red ginseng: specifically, its anti-stress action for prevention of disease. J. Pharmacol. Sci. 2004; 95 (2): 158-162.
59. Russian source
60. Kitts D., Hu C. Efficacy and safety of ginseng. Publ. Hlth Nutr. 2000; 3 (4): 473-485.
61. Chan P., Tomilinson B. Antioxidant effects of Chinese traditional medicine: focus on trilinolein isolated from the Chinese herb sanchi (Panax pseudoginseng). J. Clin. Pharmacol. 2000; 40 (5): 457-461.
62. Kim S. H., Park K. S. Effects of Panax ginseng extract on lipid metabolism in humans. Pharmacol Res. 2003; 48 (5): 511-513.
63. Chen X. C., Zhou Y. C., Chen Y. et al. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol. Sin. 2005; 26 (1): 56-62.
64. Chen X. C., Zhu Y. G., Zhu L. A. et al. Ginsenoside Rg1 attenuates dopamineinduced apoptosis in PC12 cells by suppressing oxidative stress. Eur. J. Pharmacol. 2003; 473 (1): 1-7.